Evolus, Inc. Common Stock (EOLS)

Price$6.52

Value ScoreC

Growth ScoreB

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)-16.84%

Price vs S&P 500 (4W)18.11%

VGM Score56.94

Market Capitalization$432.01M

All Metrics

Book Value / Share (Quarterly)$0.09

P/TBV (Annual)11.56x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)25.99%

Cash Flow / Share (Quarterly)$-0.68

Price vs S&P 500 (YTD)-12.29%

Gross Margin (TTM)66.06%

Net Profit Margin (TTM)-14.39%

EPS (TTM)$-0.67

10-Day Avg Trading Volume0.73M

EPS Excl Extra (TTM)$-0.67

Revenue Growth (5Y)39.38%

EPS (Annual)$-0.80

ROI (Annual)-39.69%

Gross Margin (Annual)66.33%

Net Profit Margin (5Y Avg)-32.77%

Cash / Share (Quarterly)$0.76

Revenue Growth QoQ (YoY)6.74%

ROA (Last FY)-22.86%

Revenue Growth TTM (YoY)9.56%

EBITD / Share (TTM)$-0.27

ROE (5Y Avg)-308.23%

Operating Margin (TTM)-8.06%

Cash Flow / Share (Annual)$-0.78

P/B Ratio78.23x

P/B Ratio (Quarterly)126.60x

Net Income / Employee (Annual)$-154,600

EV / Revenue (TTM)1.78x

Net Interest Coverage (TTM)-1.87x

ROA (TTM)-19.42%

EPS Incl Extra (Annual)$-0.80

Current Ratio (Annual)1.90x

Quick Ratio (Quarterly)1.61x

3-Month Avg Trading Volume1.05M

52-Week Price Return-29.76%

Revenue / Employee (TTM)$903,600

Tangible BV / Share (Quarterly)$0.31

P/S Ratio (Annual)1.45x

Asset Turnover (Annual)1.32x

52-Week High$10.62

Operating Margin (5Y Avg)-27.55%

EPS Excl Extra (Annual)$-0.80

CapEx CAGR (5Y)21.90%

26-Week Price Return-0.91%

Quick Ratio (Annual)1.49x

13-Week Price Return46.10%

Total Debt / Equity (Annual)22.00x

Current Ratio (Quarterly)2.04x

Enterprise Value$538.63M

Revenue / Share Growth (5Y)22.42%

Asset Turnover (TTM)1.35x

Revenue / Employee (Annual)$889,700

Inventory Turnover (Annual)5.12x

Pretax Margin (Annual)-17.15%

Cash / Share (Annual)$0.83

3-Month Return Std Dev90.76%

Gross Margin (5Y Avg)64.30%

Net Income / Employee (TTM)$-130,000

ROE (Last FY)-913.07%

Net Interest Coverage (Annual)-1.40x

EPS Basic Excl Extra (Annual)$-0.80

P/FCF (TTM)40.52x

Receivables Turnover (TTM)6.06x

Total Debt / Equity (Quarterly)22.00x

EPS Incl Extra (TTM)$-0.67

Receivables Turnover (Annual)5.81x

ROI (TTM)-37.81%

P/S Ratio (TTM)1.43x

Pretax Margin (5Y Avg)-32.64%

Revenue / Share (Annual)$4.61

Tangible BV / Share (Annual)$0.56

Forward P/E187.17x

Price vs S&P 500 (52W)-57.97%

Year-to-Date Return-1.35%

5-Day Price Return7.72%

EPS Normalized (Annual)$-0.80

ROA (5Y Avg)-27.43%

Net Profit Margin (Annual)-17.38%

Month-to-Date Return21.71%

Cash Flow / Share (TTM)$-1.03

EBITD / Share (Annual)$-0.41

Operating Margin (Annual)-10.99%

LT Debt / Equity (Annual)22.00x

ROI (5Y Avg)-50.30%

LT Debt / Equity (Quarterly)22.00x

EPS Basic Excl Extra (TTM)$-0.67

P/TBV (Quarterly)36.12x

P/B Ratio (Annual)126.60x

Inventory Turnover (TTM)5.88x

Pretax Margin (TTM)-14.10%

Book Value / Share (Annual)$0.09

Price vs S&P 500 (13W)36.36%

Beta1.37x

Revenue / Share (TTM)$4.63

ROE (TTM)-410.18%

52-Week Low$3.86

vGradeC

gGradeB

mGradeB

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.05est. -0.13

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.23

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
EOLSEvolus, Inc. Common Stock	C	B	B	$6.52
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
PFEPfizer Inc.	B	C	C	$25.63
ABTAbbott Laboratories	C	C	D	$87.78
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

Evolus Inc commercializes Jeuveau, a purified botulinum toxin formulation used to treat moderate to severe frown lines. The company generates revenue from product sales in the United States and Europe, and from distribution partnerships in Canada. Evolus operates in the self-pay aesthetic market, targeting physicians and consumers seeking non-invasive cosmetic treatments.